Key facts
- Notable investors include NGT HealthCare II.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Renovaris Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Renovaris Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Renovaris Pharma
Developer of a proprietary Nano-gel technology designed for the targeted non-systemic treatment of Alopecia Areata and Androgenetic Alopecia. The company offers a patent-pending system with a synergistic combination of Cyclosporine A and Tempol, enabling clients to access a long-term maintenance therapy without the Black Box risks of systemic inhibitors or the skin atrophy associated with corticosteroids.
- Sector
- Healthcare
- HQ
- Nazareth, Israel
- Founded
- 2026
- Website
- renovarispharma.com/
- Ownership
- Privately Held (backing)
Renovaris Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Renovaris Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Renovaris Pharma in its N-PORT filings yet. We sweep new filings monthly.